Outlook Therapeutics Inc. (OTLK)
Company Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte.
Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd.
The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.
Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Country | United States |
| IPO Date | Jun 14, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Lawrence A. Kenyon CPA |
Contact Details
Address: Building F Iselin, New Jersey United States | |
| Website | https://www.outlooktherapeutics.com |
Stock Details
| Ticker Symbol | OTLK |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001649989 |
| CUSIP Number | 69012T206 |
| ISIN Number | US69012T3059 |
| Employer ID | 38-3982704 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Jedd Comiskey | Senior Vice President - Head of Europe |
| Jeffrey Evanson | Chief Commercial Officer |
| Joel Prieve | Senior Vice President of Licensing and M&A |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 02, 2025 | 8-K | Current Report |
| May 28, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| May 28, 2025 | 4 | Filing |
| May 23, 2025 | 424B5 | Filing |
| May 23, 2025 | 8-K | Current Report |
| May 22, 2025 | 424B5 | Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |